Today: 21 May 2026
Quantum Computing Stocks Slip Into New Year Holiday as Traders Eye CES, Earnings Next

Quantum Computing Stocks Slip Into New Year Holiday as Traders Eye CES, Earnings Next

NEW YORK, January 1, 2026, 13:13 ET — Market closed

  • Quantum computing stocks ended the last U.S. session of 2025 mostly lower, led by declines in IonQ, Rigetti and Quantum Computing Inc.
  • Thin, holiday-shortened trading left high-volatility names exposed to profit-taking as Wall Street closed out a strong year.
  • Investors are now looking to CES 2026 and the next round of earnings for clearer signals on demand and cash burn.

Quantum computing stocks ended 2025 on a softer note, with several of the sector’s most traded names closing lower ahead of the New Year’s Day market holiday. IonQ, Rigetti Computing, D-Wave Quantum and Quantum Computing Inc. all fell in the final regular U.S. session of the year.

The moves matter because quantum shares have become a high-beta corner of the market, where small shifts in risk appetite can produce outsized swings. Investors are also entering 2026 with a sharper focus on valuation, as most pure-play quantum companies remain loss-making while promising long development timelines.

Holiday trading conditions amplified that sensitivity. “Profit-taking opportunities when liquidity was low,” helped drive late-year moves, said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

In the last close on Wednesday, IonQ fell 0.9% to $44.87, Rigetti slipped 1.1% to $22.15, D-Wave dipped 0.4% to $26.15, and Quantum Computing Inc. slid 1.3% to $10.26. IBM, which also invests heavily in quantum computing, dropped 1.9% to $296.21.

A research note published on Wednesday by Zacks Investment Research highlighted how investors are weighing long-term buildouts against near-term revenue. In that note, Zacks said Quantum Computing Inc. is investing in “Fab 1” and planning a larger “Fab 2” facility over the next three years, a strategy it said supports scaling but can constrain near-term sales. TradingView

Zacks also flagged valuation risk, noting that Quantum Computing Inc. traded at a forward 12-month price-to-sales ratio of about 731. Price-to-sales compares a company’s market value with expected revenue, and is often used for firms that do not yet generate profits.

The same Zacks note pointed to differing business models across peers. It said Rigetti has leaned on a mix of government contracts and cloud-based quantum services, while IonQ has shown revenue growth and improving balance sheet metrics but continues to operate at a loss.

Quantum computing is still at an early commercial stage. The technology uses “qubits” — quantum bits — that can represent more than one state at a time, potentially accelerating certain calculations, though scaling systems reliably remains difficult.

The broader backdrop was also cautious into the year’s final close. Wall Street’s main indexes ended Wednesday lower in thin trading, though all three posted sizable gains for 2025, Reuters reported.

U.S. stock markets are closed on Thursday for New Year’s Day, according to the NYSE calendar and Nasdaq’s holiday schedule.

Before the next session on Friday, investors will watch whether risk appetite returns as normal liquidity comes back, especially in the most volatile corners of tech. For quantum names, the focus remains on customer wins, cash burn and any signals that commercial demand is moving beyond pilot projects.

Traders are also looking ahead to CES 2026 in Las Vegas, scheduled for January 6–9, which often serves as an early-year stage for technology roadmaps and partnerships.

Earnings are the next hard catalysts, though dates can shift. Zacks’ calendars list IonQ’s next report as expected on February 25, with Rigetti expected on March 4, D-Wave expected on March 12, and Quantum Computing Inc. expected on March 19.

Stock Market Today

  • Lean Hog Futures Fall; USDA Reports Lower Prices and Slaughter Numbers
    May 20, 2026, 8:21 PM EDT. Lean hog futures closed lower Wednesday, with contracts down 17 cents to $1 across most months. The USDA's national base hog price fell $1.11 to $93.76, while the CME Lean Hog Index inched up 5 cents to $90.55 on May 18. The pork carcass cutout value dropped $1.41 to $95.47 per hundredweight, with only the butt primal showing gains. Federally inspected hog slaughter was estimated at 482,000 head Wednesday, down 8,000 from the previous week and over 24,000 less than the same week last year. Market pressure reflects supply adjustments amid falling prices, signaling cautious trading conditions in the lean hog sector.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Robinhood stock today: HOOD slides after December trading snapshot and Goldman target trim
Previous Story

Robinhood stock today: HOOD slides after December trading snapshot and Goldman target trim

Gold price forecast for 2026: Banks map a $4,275-$5,000 range after bullion’s blockbuster year
Next Story

Gold price forecast for 2026: Banks map a $4,275-$5,000 range after bullion’s blockbuster year

Go toTop